ARS Pharmaceuticals (SPRY) said its licensing partners in China, Japan and Australia have submitted approval applications for its epinephrine nasal spray called neffy 2 mg.
The phase 3 trial of the nasal spray in Japanese patients aged 6 to 17, who had anaphylactic symptoms after food, had a 100% success rate in removing symptoms in about 16 minutes, the company said Thursday in a statement.
Additional tests in China matched US studies with similar results, the company said.
The treatment is approved in the US for severe allergic reactions.
Price: 12.50, Change: +0.23, Percent Change: +1.87
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。